Overview

The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment

Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
Prostate cancer (PrCa) is one of the commonest cancer in men in the Western world, with over 40,000 new cases diagnosed each year in the United Kingdom (UK). Research studies have identified several genetic changes that are thought to increase the risk of developing prostate cancer. Some of these genetic changes occur in deoxyribonucleic acid (DNA) repair genes. The BARCODE 2 trial is formed of two parts that aim to investigate how having genetic changes in DNA repair genes can affect response to carboplatin treatment in patients with metastatic castration resistant prostate cancer (mCRPC). In part 1 of the study, the investigators will invite men with mCRPC who have not had genetic testing before to join the study by initially undergoing genetic screening within the study. The DNA repair gene mutation carrier status of enrolled patients will be assessed using a gene panel. If a pathogenic mutation is confirmed in one of these genes, patients will be given the option to proceed to part 2 of the study. In part 2 of the study, men with mCRPC who are known to be carriers of a mutation in DNA repair gene(s) will be assessed for eligibility for treatment on the study with carboplatin chemotherapy. The aim of the study will be to determine how patients with mCRPC and a germline mutation in a DNA repair gene(s) respond to platinum chemotherapy. This study will help researchers to investigate platinum sensitivity of prostate tumours that have developed due to a germline mutation in a DNA repair gene. This study will provide data to use in a larger clinical trial of platinum chemotherapy based on patients' germline genetic signature and/or tumour genetic profile.
Phase:
Phase 2
Details
Lead Sponsor:
Institute of Cancer Research, United Kingdom
Collaborators:
Barts & The London NHS Trust
Buckinghamshire Healthcare NHS Trust
Chelsea and Westminster NHS Foundation Trust
Colchester Hospital University NHS Foundation Trust
Dartford and Gravesham NHS Foundation Trust
East and North Hertfordshire NHS Trust
European Research Council
Frimley Park Hospital NHS Trust
Great Ormond Street Hospital for Children NHS Foundation Trust
Heatherwood and Wexham Park Hospitals NHS Foundation Trust
Imperial College Healthcare NHS Trust
Luton and Dunstable Hospital NHS Foundation Trust
Maidstone & Tunbridge Wells NHS Trust
Medway NHS Foundation Trust
Mid and South Essex NHS Foundation Trust
North Middlesex University Hospital NHS Trust
Northampton General Hospital NHS Trust
Nottingham University Hospitals NHS Trust
Royal Devon and Exeter NHS Foundation Trust
Royal Free Hampstead NHS Trust
Royal Marsden NHS Foundation Trust
Royal Surrey County Hospital NHS Foundation Trust
Southend University Hospital Foundation NHS Trust
The Whittington Hospital NHS Trust
Whipps Cross University NHS Trust
Yeovil District Hospital NHS Foundation Trust
Treatments:
Carboplatin